Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | esophagus squamous cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | esophagus squamous cell carcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a preferred second-line therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma with CD274 (PD-L1) expression (CPS >/=10) (NCCN.org). | detail... |
CD274 positive | esophagus squamous cell carcinoma | sensitive | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-181) that supported FDA approval, Keytruda (pembrolizumab) treatment as second-line therapy improved overall survival (OS) (9.3 vs 6.7 months, HR=0.69, p=0.0074) and 12-month OS rate (43% vs 20%) compared to chemotherapy in patients with esophagus squamous cell carcinoma with a CPS of 10 or higher (PMID: 33026938; NCT02564263). | detail... detail... 33026938 |
CD274 positive | esophagus squamous cell carcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, CPS>=10), and as second or subsequent lines of treatment for previously treated patients who have not received immunotherapy and with CPS>=10 (PMID: 35914638; ESMO.org). | detail... 35914638 |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... | |
ESMO Clinical Practice Guidelines | Full reference... | |
Full reference... | ||
Keytruda (pembrolizumab) FDA Drug Label | Full reference... | |
(33026938) | Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. | Full reference... |
(35914638) | Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Full reference... |